Identification of tumor-associated HLA-ligands in the post-genomic era.
Over 10 years ago, the identification of the first tumor-specific T cell epitope shed light on the molecular principles underlying the phenomenon of tumor eradication by the immune system. Since then, a considerable number of different approaches for this task have been introduced and employed successfully, reflecting the growing knowledge about the cellular processes preceding antigen presentation as well as significant technical developments. This review tries to give an overview over available conventional strategies as well as current developments that utilize the potent large-scale screening tools of the post-genomic era.
Schirle
Markus
M
Department of Immunology, Institute for Cell Biology, University of Tübingen, Germany. markus.schirle@cellzome.com
D000818:Animals; D000951:Antigens, Neoplasm / Q000032:analysis* / Q000276:immunology; D004353:Drug Evaluation, Preclinical / Q000379:methods; D000939:Epitopes / Q000032:analysis; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D013601:T-Lymphocytes / Q000276:immunology
D000951:Antigens, Neoplasm; D000939:Epitopes; D006680:HLA Antigens